167 related articles for article (PubMed ID: 20436341)
1. Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase.
Sigmond J; Bergman AM; Leon LG; Loves WJ; Hoebe EK; Peters GJ
Anticancer Drugs; 2010 Jul; 21(6):591-9. PubMed ID: 20436341
[TBL] [Abstract][Full Text] [Related]
2. The role of deoxycytidine kinase in gemcitabine cytotoxicity.
van der Wilt CL; Kroep JR; Bergman AM; Loves WJ; Alvarez E; Talianidis I; Eriksson S; van Groeningen CJ; Pinedo HM; Peters GJ
Adv Exp Med Biol; 2000; 486():287-90. PubMed ID: 11783501
[No Abstract] [Full Text] [Related]
3. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.
Bergman AM; Pinedo HM; Talianidis I; Veerman G; Loves WJ; van der Wilt CL; Peters GJ
Br J Cancer; 2003 Jun; 88(12):1963-70. PubMed ID: 12799644
[TBL] [Abstract][Full Text] [Related]
4. Steroids affect collateral sensitivity to gemcitabine of multidrug-resistant human lung cancer cells.
Bergman AM; Pinedo HM; Peters GJ
Eur J Pharmacol; 2001 Mar; 416(1-2):19-24. PubMed ID: 11282108
[TBL] [Abstract][Full Text] [Related]
5. The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent.
Sigmond J; Kamphuis JA; Laan AC; Hoebe EK; Bergman AM; Peters GJ
Biochem Pharmacol; 2007 May; 73(10):1548-57. PubMed ID: 17324380
[TBL] [Abstract][Full Text] [Related]
6. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
[TBL] [Abstract][Full Text] [Related]
7. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
Giovannetti E; Mey V; Danesi R; Basolo F; Barachini S; Deri M; Del Tacca M
Br J Cancer; 2005 Feb; 92(4):681-9. PubMed ID: 15700043
[TBL] [Abstract][Full Text] [Related]
8. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
Kroep JR; van Moorsel CJ; Veerman G; Voorn DA; Schultz RM; Worzalla JF; Tanzer LR; Merriman RL; Pinedo HM; Peters GJ
Adv Exp Med Biol; 1998; 431():657-60. PubMed ID: 9598147
[No Abstract] [Full Text] [Related]
9. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
Shord SS; Patel SR
J Exp Clin Cancer Res; 2009 Jun; 28(1):76. PubMed ID: 19500405
[TBL] [Abstract][Full Text] [Related]
11. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R
Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562
[TBL] [Abstract][Full Text] [Related]
12. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
Liu XQ; Wang WX; Lin L; Song ST
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
[TBL] [Abstract][Full Text] [Related]
13. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
[TBL] [Abstract][Full Text] [Related]
14. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
[TBL] [Abstract][Full Text] [Related]
15. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
Davidson JD; Ma L; Flagella M; Geeganage S; Gelbert LM; Slapak CA
Cancer Res; 2004 Jun; 64(11):3761-6. PubMed ID: 15172981
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
Kroep JR; Loves WJ; van der Wilt CL; Alvarez E; Talianidis I; Boven E; Braakhuis BJ; van Groeningen CJ; Pinedo HM; Peters GJ
Mol Cancer Ther; 2002 Apr; 1(6):371-6. PubMed ID: 12477049
[TBL] [Abstract][Full Text] [Related]
17. mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer.
Tian L; Chen C; Guo Y; Zhang F; Mi J; Feng Q; Lin S; Xi N; Tian J; Yu L; Chen Y; Cao M; Lai C; Fan J; Zhang Y; Chen G
Neoplasia; 2021 Jul; 23(7):643-652. PubMed ID: 34126361
[TBL] [Abstract][Full Text] [Related]
18. siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine.
Di Cresce C; Figueredo R; Rytelewski M; Maleki Vareki S; Way C; Ferguson PJ; Vincent MD; Koropatnick J
Oncotarget; 2015 Sep; 6(26):22397-409. PubMed ID: 26087398
[TBL] [Abstract][Full Text] [Related]
19. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
Al-Madhoun AS; van der Wilt CL; Loves WJ; Padron JM; Eriksson S; Talianidis I; Peters GJ
Biochem Pharmacol; 2004 Aug; 68(4):601-9. PubMed ID: 15276067
[TBL] [Abstract][Full Text] [Related]
20. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells.
Giovannetti E; Mey V; Nannizzi S; Pasqualetti G; Marini L; Del Tacca M; Danesi R
Mol Pharmacol; 2005 Jul; 68(1):110-8. PubMed ID: 15795320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
